rihanna oü
TauroLock U25.000
TauroLock U25.000
Couldn't load pickup availability
TauroLock™-U25.000
Our product range includes specialised catheter lock solutions for patients in different contexts. TauroLock™-U25.000 ensures a particularly strong prophylaxis against occlusion, thanks to the active ingredient urokinase.
Indication and effect
TauroLock™-U25.000 has been approved for instillation in all central-venous access systems. This lock solution reliably prevents the formation of bacterial biofilms within catheters: Patients can avoid infections and maintain a high patency rate.
Composition
TauroLock™-U25.000 is based on three active ingredients:
- taurolidine
- citrate (4 %)
- urokinase (25,000 units per ml)
Taurolidine has a broad antimicrobial activity (incl. MRSA and VRE), while citrate works as an anticoagulant. Urokinase has a thrombolytic effect, breaking up blood clotting in its early stages.
Application
Before applying TauroLock™-U25.000, you need to dissolve the vial’s content (i.e. 25,000 IU urokinase) with 5 ml of TauroLock™. In-between treatment sessions, instil the clear, colourless solution into the vascular access system (VAD). Please note that medical staff should check the filling volume of each catheter or port system.
Share
